ClinConnect ClinConnect Logo
Search / Trial NCT01947556

Insulin by Jet-injection for Hyperglycemia in Diabetes

Launched by UNIVERSITY MEDICAL CENTER NIJMEGEN · Sep 17, 2013

Trial Information

Current as of May 14, 2025

Completed

Keywords

Diabetes Insulin Administration Hyperglycaemia Insulin Aspart

ClinConnect Summary

Recently, we showed in both healthy, non-diabetic volunteers and in patients with type 1 (T1DM) and insulin-treated type 2 diabetes (T2DM) a 40-50% faster absorption of rapid-acting insulin analogues when administered by jet injection technology rather than by conventional insulin pen. The faster insulin action of insulin administration by jet injection may be especially advantageous for correction of hyperglycemia.

To investigate this, a open-label randomised controlled cross-over study will be performed in 20 adult patients (18-75 years) with T1DM or T2DM on basal-bolus insulin treatment...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • diabetes mellitus type 1 or 2
  • Age 18-75 years
  • Body-Mass Index ≥25 kg/m2 and ≤40 kg/m2
  • Stable glycaemic control with HbA1c ≥48 (6.5%) and ≤86 mmol/mol (10%)
  • Insulin treatment according to basal-bolus regimen, i.e. by multiple daily injections at least four times daily, or by subcutaneous insulin pump, for at least 12 months, use of metformin allowed
  • Exclusion Criteria:
  • Inability to provide informed consent
  • Insulin requirement of \<34 or \>200 units per day
  • Treatment with systemic corticosteroids, immunosuppressive or cytostatic drugs
  • Known allergy to aspart insulin
  • Use of oral antidiabetic drugs other than metformin
  • Symptomatic diabetic neuropathy
  • History of a major cardiovascular disease event (myocardial infarction, stroke, symptomatic peripheral artery disease, coronary bypass surgery, percutaneous coronary or peripheral artery angioplasty) in the previous 6 months
  • Pregnancy or the intention to become pregnant
  • Renal disease (creatinine \>150 μmol/l or MDRD-GFR \<30 ml/min/1.73m2)
  • Liver disease (aspartate aminotransferase or alanine aminotransferase level of more than three times the upper limit of normal range)
  • Presence of any other medical condition that might interfere with the study protocol
  • anemia

About University Medical Center Nijmegen

University Medical Center Nijmegen (UMC Nijmegen) is a leading academic medical center located in the Netherlands, renowned for its commitment to innovative research, high-quality patient care, and advanced medical education. As a key player in clinical trials, UMC Nijmegen leverages its multidisciplinary expertise and state-of-the-art facilities to conduct pioneering studies that aim to enhance treatment options and improve health outcomes. The center collaborates with various national and international partners to foster translational research, ensuring that scientific advancements are effectively integrated into clinical practice. With a strong focus on ethical standards and patient safety, UMC Nijmegen is dedicated to contributing valuable insights to the global medical community.

Locations

Nijmegen, , Netherlands

Nijmegen, , Netherlands

Patients applied

0 patients applied

Trial Officials

Bastiaan de Galan, MD PhD

Study Chair

Radboud University Medical Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials